GLP-1 injury dockets reach 4,022 and 216 pending cases

Federal court statistics released by the U.S. Judicial Panel on Multidistrict Litigation (JPML) show 4,022 lawsuits pending in the consolidated GLP-1 products liability case, with 4,056 actions filed to date. A second, newer docket covering claims of an eye injury called non-arteritic anterior ischemic optic neuropathy (NAION) listed 216 pending actions out of 216 filed ^[1].

Both dockets sit before the same judge. The report lists Judge Karen S. Marston of the U.S. District Court for the Eastern District of Pennsylvania as presiding over MDL 3094, "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation," and MDL 3163, "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation" ^[1].

What the numbers mean

A multidistrict litigation, or MDL, is a way the federal court system groups similar lawsuits filed around the country in front of one judge for pretrial work such as document exchange and expert testimony. The JPML publishes a monthly snapshot counting how many cases are pending in each MDL and how many have been filed historically ^[1].

The gap between the two figures is informative. In MDL 3094, 4,022 of the 4,056 cases ever filed are still pending, meaning only a small number have been closed or resolved so far ^[1]. In MDL 3163, the pending count and the historical count are identical at 216, which is typical of a docket that was created recently and has not yet seen cases dismissed or otherwise concluded ^[1].

For scale, the GLP-1 docket ranked 12th by pending actions on the September 1, 2026 list. The largest was the Johnson & Johnson talcum powder litigation in New Jersey, with 69,250 pending actions, followed by Bard hernia mesh at 23,316 and aqueous film-forming foams at 15,264 ^[1]. Other pharmaceutical dockets of comparable size to the GLP-1 case include Depo-Provera at 6,403 pending and Paragard IUD at 4,185 ^[1]. The Roundup litigation listed 3,925 pending, slightly below the GLP-1 total ^[1].

The report is a statistical table only. It does not describe what injuries plaintiffs allege, which drugs or manufacturers are named, how strong the claims are, or whether any court has found the medications caused harm. Those details are not in this source. The report also does not include state-court lawsuits, so the federal numbers are not a complete count of GLP-1 litigation nationwide ^[1].

Why it matters for patients

A rising case count in an MDL is a measure of legal activity, not a measure of medical risk. Courts consolidate cases when many similar complaints are filed; that step happens long before any judge or jury weighs the scientific evidence on whether a drug caused a specific injury. Nothing in this report establishes that semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or any other GLP-1 medication causes the injuries alleged.

Still, the two dockets are worth tracking for a practical reason: litigation often runs alongside regulatory and scientific review of a safety question, and pretrial proceedings can surface internal company documents and expert analyses that later become public. The existence of a separate NAION docket shows the panel considered eye-injury claims distinct enough to manage on their own track ^[1].

Patients who have questions about side effects they are experiencing, or about label warnings for a drug they take, generally raise those with the clinician who prescribed it. This report does not offer guidance on that.

What happens next

The JPML updates this distribution report monthly, so the next snapshot after the September 1, 2026 figures will show whether filings in either docket are accelerating or leveling off ^[1]. Specific case-management deadlines, bellwether trial dates and any rulings by Judge Marston are not included in this statistics report and are not yet known from this source.